Notably, patients with immediate combination of Gem/Cis with durvalumab alone or durvalumab plus tremelimumab displayed high objective responses of approximately 70%.220While adding tremelimumab to the regimen achieved no additional benefit in ORR and OS, the combination of durvalumab and Gem/Cis has been further explored in the phase III TOPAZ-1 trial,221which tested the anti-PD-L1 drug durvalumab with chemotherapy (n = 341) compared to placebo with chemotherapy (n = 344) in patients with advanced CCA. Here, CD274 is linked to cholangiocarcinoma.